Distrito de Innovación Tlalpan biomedical ecosystem in Mexico, Digi Mart USA News (Mexico City): The Distrito de Innovación Tlalpan (DiT) has announced the consolidation of the first ecosystem in Mexico designed to connect all stages of future medicine, from basic scientific research to the production and application of biotechnological treatments in people.
The collaborative platform, driven by the Tecnológico de Monterrey, carries an investment of more than 4,544 million pesos and will bring together two high-impact projects. The ecosystem aims to address one of the largest historical challenges in Mexican science: the disconnect between academia and the hospital.
Many national medical discoveries have traditionally stalled in university laboratories due to a lack of resources for clinical trials or production facilities. Through this joint project, Mexican science will gain the infrastructure needed to apply research and turn it into medicines and therapies accessible to the population.
David Garza, executive president of the Tecnológico de Monterrey Educational Group, said the center reflects the institution’s purpose of transforming lives and communities through education, science and humane purpose. “The best way to predict the future is to invent it ourselves, and that is precisely what we are trying to do in the Tlalpan District,” he said.
The Tecnológico de Monterrey’s Center for Interdisciplinary Medicine and Precision Health (CIMP) will operate under an interdisciplinary model in collaboration with the Institute of Biotechnology and the Faculty of Chemistry of the National Autonomous University of Mexico (UNAM). Its work will focus on three strategic lines: precision oncology, healthy aging and biopharmacy, with an emphasis on identifying biomarkers for early detection of prostate and lung cancer, as well as neurodegenerative and cardiometabolic conditions.
The center’s physical budget is 20 million dollars, supplemented by a target of raising an additional 23 million pesos in research funding. Avant Santé will develop infrastructure to offer research, manufacturing and formulation services under Good Manufacturing Practices (GMP).
This will allow Mexico to locally produce and assemble supplies and kits for clinical trials that the country currently must buy abroad, substituting imports and attracting international investment through pharmaceutical nearshoring.
Raju Yarramraju, CEO of Avant Santé, said his company’s aspiration is to help more discoveries reach the point where they improve people’s lives and to make Mexico a destination where that path is possible.
The effort aligns with the objectives of the Plan México, which seeks to raise national clinical research to 2 billion dollars annually and position the country as an international biotechnology cluster. Economy Secretary Marcelo Ebrard noted that the country has a concentration of more than 25,000 health professionals, exceeding that of many large cities worldwide.
The Tlalpan District ecosystem also formally incorporated the Mexican Foundation for Health (FUNSALUD) to develop academic and research projects. The announcement also included the arrival in Mexico City of Venture Café Connect, a global open innovation network born in Cambridge, Massachusetts, which will serve as a space for ongoing connection among scientists, entrepreneurs, industry and investment funds.
Clara Brugada, head of government of Mexico City, described the investment of more than 4 billion pesos in biotechnology as an example of the economic future the city aims to build.
